Treatment Of Ductal Carcinoma In Situ

Ductal carcinoma in situ(DCIS)is a pre-invasive stage of breast cancer,but not all DCIS will progress to invasive breast cancer.Since the introduction of mammographic screening programmes,the incidence of DCIS has shown a dramatic increase.Unlike invasive breast cancer,the clinical focus of DCIS is mainly to prevent its local recurrence(rather than mortality)and progression to invasive breast cancer.Although there is ample evidence that breast-conserving surgery and total mastectomy have similar postoperative recurrence rates for DCIS patients,however,the current surgical treatment of DCIS is still using mastectomy more.And for the width of the margin of breast conservation surgery,most scholars admire the width of the 2mm negative margin,but no consensus has been reached.According to the patient's condition,sentinel lymph node biopsy may be considered to avoid a larger surgical trauma caused by axillary lymph node dissection in the course of surgical treatment.It has also been supported by a large number of clinical trial data that taking endocrine medication for hormone receptor-positive patients can prevent their local recurrence.However,the efficacy of targeted therapy for HER-2 positive patients and chemotherapy has not been determined in the treatment of DCIS patients.